Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy
Abstract MicroRNAs (miRNAs) play critical roles in modulating the oncogenic driver pathways involved in the acquisition of resistance to cancer treatments. MiR-542-3p serves as a potent tumor suppressor molecule by targeting tumor suppressor p53 and apoptosis inhibitor survivin. A hyaluronic acid (H...
Gespeichert in:
| Veröffentlicht in: | Nanomedicine 2016-02, Vol.12 (2), p.411-420 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 420 |
|---|---|
| container_issue | 2 |
| container_start_page | 411 |
| container_title | Nanomedicine |
| container_volume | 12 |
| creator | Wang, Shengpeng, MS Zhang, Jinming, MS Wang, Yitao, MS Chen, Meiwan, PhD |
| description | Abstract MicroRNAs (miRNAs) play critical roles in modulating the oncogenic driver pathways involved in the acquisition of resistance to cancer treatments. MiR-542-3p serves as a potent tumor suppressor molecule by targeting tumor suppressor p53 and apoptosis inhibitor survivin. A hyaluronic acid (HA)-decorated polyethylenimine-poly( d , l -lactide-co-glycolide) (PEI-PLGA) nanoparticle system was developed in this study for targeted co-delivery of doxorubicin (DOX) and miR-542-3p for triple negative breast cancer (TNBC) therapy. This system showed an average size at 131.7 nm and high drug encapsulation efficiency, and prevented miR-542-3p degradation in the serum. HA/PEI-PLGA nanoparticles increased both drug uptake and cytotoxicity in MDA-MB-231 cells compared to MCF-7 cells, which express lower CD44 levels. Intracellular restoration of miR-542-3p further promoted TNBC cell apoptosis via activating p53 and inhibiting survivin expression. These results indicate that HA/PEI-PLGA nanoparticles have the potential to co-deliver chemotherapeutic agents and tumor suppressive miRNAs in combinatorial TNBC therapy. |
| doi_str_mv | 10.1016/j.nano.2015.09.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1790956381</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1549963415005948</els_id><sourcerecordid>1790956381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c514t-f23e49c3c2331b5e97342490735af7a01530d971e72bab85f3c532c78b4698753</originalsourceid><addsrcrecordid>eNp9ks1u1TAUhC0EoqXwAiyQl2wc_BvHEkKqqtJWuhIVP2vLcU7Al9w42ElFXoGnxuGWLliwsqUzM5a_OQi9ZLRilNVv9tXoxlhxylRFTUWZfIROmZKGmFryxw93IU_Qs5z3lApNqXmKTnitGTN1c4p-Xa9uWFIcg8fOh4746Gbo8O3lDbndXZ3j7YnJpTn4ATI-QBf-zH0kHQzhDtKKY4-7-DOmpQ0-jNiNHT6Ej0RJTsSE-5jwnMI0AB7hq5uLB7cJXJ6xd6OHMv0GyU3rc_Skd0OGF_fnGfry_vLzxTXZfbi6uTjfEa-YnEnPBUjjhedCsFaB0UJyaagWyvXaFRiCdkYz0Lx1baN64ZXgXjetrE2jlThDr4-5U4o_FsizPYTsYRjcCHHJlmlDjapFw4qUH6U-xZwT9HZK4eDSahm1Wwd2bzdAduvAUmNLB8X06j5_aQuvB8tf6EXw9iiA8su7AMlmH6Cg6EICP9suhv_nv_vH7odQ-nPDd1gh7-OSxsLPMpu5pfbTtgXbEjBFqTKyEb8Byb6stA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1790956381</pqid></control><display><type>article</type><title>Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Wang, Shengpeng, MS ; Zhang, Jinming, MS ; Wang, Yitao, MS ; Chen, Meiwan, PhD</creator><creatorcontrib>Wang, Shengpeng, MS ; Zhang, Jinming, MS ; Wang, Yitao, MS ; Chen, Meiwan, PhD</creatorcontrib><description>Abstract MicroRNAs (miRNAs) play critical roles in modulating the oncogenic driver pathways involved in the acquisition of resistance to cancer treatments. MiR-542-3p serves as a potent tumor suppressor molecule by targeting tumor suppressor p53 and apoptosis inhibitor survivin. A hyaluronic acid (HA)-decorated polyethylenimine-poly( d , l -lactide-co-glycolide) (PEI-PLGA) nanoparticle system was developed in this study for targeted co-delivery of doxorubicin (DOX) and miR-542-3p for triple negative breast cancer (TNBC) therapy. This system showed an average size at 131.7 nm and high drug encapsulation efficiency, and prevented miR-542-3p degradation in the serum. HA/PEI-PLGA nanoparticles increased both drug uptake and cytotoxicity in MDA-MB-231 cells compared to MCF-7 cells, which express lower CD44 levels. Intracellular restoration of miR-542-3p further promoted TNBC cell apoptosis via activating p53 and inhibiting survivin expression. These results indicate that HA/PEI-PLGA nanoparticles have the potential to co-deliver chemotherapeutic agents and tumor suppressive miRNAs in combinatorial TNBC therapy.</description><identifier>ISSN: 1549-9634</identifier><identifier>EISSN: 1549-9642</identifier><identifier>DOI: 10.1016/j.nano.2015.09.014</identifier><identifier>PMID: 26711968</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antibiotics, Antineoplastic - administration & dosage ; Antibiotics, Antineoplastic - pharmacology ; Apoptosis ; Apoptosis - drug effects ; Breast - drug effects ; Breast - metabolism ; Breast - pathology ; Breast cancer ; Cell Line, Tumor ; Doxorubicin ; Doxorubicin - administration & dosage ; Doxorubicin - pharmacology ; Drug Carriers - chemistry ; Female ; Gene Expression Regulation, Neoplastic ; Genetic Therapy ; Humans ; Hyaluronic acid ; Hyaluronic Acid - chemistry ; Internal Medicine ; Lactic Acid - chemistry ; MicroRNA ; MicroRNAs - administration & dosage ; MicroRNAs - pharmacology ; Nanoparticles - chemistry ; Polyethyleneimine - chemistry ; Polyglycolic Acid - chemistry ; Polylactic Acid-Polyglycolic Acid Copolymer ; Triple Negative Breast Neoplasms - genetics ; Triple Negative Breast Neoplasms - pathology ; Triple Negative Breast Neoplasms - therapy</subject><ispartof>Nanomedicine, 2016-02, Vol.12 (2), p.411-420</ispartof><rights>Elsevier Inc.</rights><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c514t-f23e49c3c2331b5e97342490735af7a01530d971e72bab85f3c532c78b4698753</citedby><cites>FETCH-LOGICAL-c514t-f23e49c3c2331b5e97342490735af7a01530d971e72bab85f3c532c78b4698753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1549963415005948$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26711968$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Shengpeng, MS</creatorcontrib><creatorcontrib>Zhang, Jinming, MS</creatorcontrib><creatorcontrib>Wang, Yitao, MS</creatorcontrib><creatorcontrib>Chen, Meiwan, PhD</creatorcontrib><title>Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy</title><title>Nanomedicine</title><addtitle>Nanomedicine</addtitle><description>Abstract MicroRNAs (miRNAs) play critical roles in modulating the oncogenic driver pathways involved in the acquisition of resistance to cancer treatments. MiR-542-3p serves as a potent tumor suppressor molecule by targeting tumor suppressor p53 and apoptosis inhibitor survivin. A hyaluronic acid (HA)-decorated polyethylenimine-poly( d , l -lactide-co-glycolide) (PEI-PLGA) nanoparticle system was developed in this study for targeted co-delivery of doxorubicin (DOX) and miR-542-3p for triple negative breast cancer (TNBC) therapy. This system showed an average size at 131.7 nm and high drug encapsulation efficiency, and prevented miR-542-3p degradation in the serum. HA/PEI-PLGA nanoparticles increased both drug uptake and cytotoxicity in MDA-MB-231 cells compared to MCF-7 cells, which express lower CD44 levels. Intracellular restoration of miR-542-3p further promoted TNBC cell apoptosis via activating p53 and inhibiting survivin expression. These results indicate that HA/PEI-PLGA nanoparticles have the potential to co-deliver chemotherapeutic agents and tumor suppressive miRNAs in combinatorial TNBC therapy.</description><subject>Antibiotics, Antineoplastic - administration & dosage</subject><subject>Antibiotics, Antineoplastic - pharmacology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Breast - drug effects</subject><subject>Breast - metabolism</subject><subject>Breast - pathology</subject><subject>Breast cancer</subject><subject>Cell Line, Tumor</subject><subject>Doxorubicin</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - pharmacology</subject><subject>Drug Carriers - chemistry</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genetic Therapy</subject><subject>Humans</subject><subject>Hyaluronic acid</subject><subject>Hyaluronic Acid - chemistry</subject><subject>Internal Medicine</subject><subject>Lactic Acid - chemistry</subject><subject>MicroRNA</subject><subject>MicroRNAs - administration & dosage</subject><subject>MicroRNAs - pharmacology</subject><subject>Nanoparticles - chemistry</subject><subject>Polyethyleneimine - chemistry</subject><subject>Polyglycolic Acid - chemistry</subject><subject>Polylactic Acid-Polyglycolic Acid Copolymer</subject><subject>Triple Negative Breast Neoplasms - genetics</subject><subject>Triple Negative Breast Neoplasms - pathology</subject><subject>Triple Negative Breast Neoplasms - therapy</subject><issn>1549-9634</issn><issn>1549-9642</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks1u1TAUhC0EoqXwAiyQl2wc_BvHEkKqqtJWuhIVP2vLcU7Al9w42ElFXoGnxuGWLliwsqUzM5a_OQi9ZLRilNVv9tXoxlhxylRFTUWZfIROmZKGmFryxw93IU_Qs5z3lApNqXmKTnitGTN1c4p-Xa9uWFIcg8fOh4746Gbo8O3lDbndXZ3j7YnJpTn4ATI-QBf-zH0kHQzhDtKKY4-7-DOmpQ0-jNiNHT6Ej0RJTsSE-5jwnMI0AB7hq5uLB7cJXJ6xd6OHMv0GyU3rc_Skd0OGF_fnGfry_vLzxTXZfbi6uTjfEa-YnEnPBUjjhedCsFaB0UJyaagWyvXaFRiCdkYz0Lx1baN64ZXgXjetrE2jlThDr4-5U4o_FsizPYTsYRjcCHHJlmlDjapFw4qUH6U-xZwT9HZK4eDSahm1Wwd2bzdAduvAUmNLB8X06j5_aQuvB8tf6EXw9iiA8su7AMlmH6Cg6EICP9suhv_nv_vH7odQ-nPDd1gh7-OSxsLPMpu5pfbTtgXbEjBFqTKyEb8Byb6stA</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Wang, Shengpeng, MS</creator><creator>Zhang, Jinming, MS</creator><creator>Wang, Yitao, MS</creator><creator>Chen, Meiwan, PhD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20160201</creationdate><title>Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy</title><author>Wang, Shengpeng, MS ; Zhang, Jinming, MS ; Wang, Yitao, MS ; Chen, Meiwan, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c514t-f23e49c3c2331b5e97342490735af7a01530d971e72bab85f3c532c78b4698753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antibiotics, Antineoplastic - administration & dosage</topic><topic>Antibiotics, Antineoplastic - pharmacology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Breast - drug effects</topic><topic>Breast - metabolism</topic><topic>Breast - pathology</topic><topic>Breast cancer</topic><topic>Cell Line, Tumor</topic><topic>Doxorubicin</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - pharmacology</topic><topic>Drug Carriers - chemistry</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genetic Therapy</topic><topic>Humans</topic><topic>Hyaluronic acid</topic><topic>Hyaluronic Acid - chemistry</topic><topic>Internal Medicine</topic><topic>Lactic Acid - chemistry</topic><topic>MicroRNA</topic><topic>MicroRNAs - administration & dosage</topic><topic>MicroRNAs - pharmacology</topic><topic>Nanoparticles - chemistry</topic><topic>Polyethyleneimine - chemistry</topic><topic>Polyglycolic Acid - chemistry</topic><topic>Polylactic Acid-Polyglycolic Acid Copolymer</topic><topic>Triple Negative Breast Neoplasms - genetics</topic><topic>Triple Negative Breast Neoplasms - pathology</topic><topic>Triple Negative Breast Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Shengpeng, MS</creatorcontrib><creatorcontrib>Zhang, Jinming, MS</creatorcontrib><creatorcontrib>Wang, Yitao, MS</creatorcontrib><creatorcontrib>Chen, Meiwan, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Nanomedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Shengpeng, MS</au><au>Zhang, Jinming, MS</au><au>Wang, Yitao, MS</au><au>Chen, Meiwan, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy</atitle><jtitle>Nanomedicine</jtitle><addtitle>Nanomedicine</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>12</volume><issue>2</issue><spage>411</spage><epage>420</epage><pages>411-420</pages><issn>1549-9634</issn><eissn>1549-9642</eissn><abstract>Abstract MicroRNAs (miRNAs) play critical roles in modulating the oncogenic driver pathways involved in the acquisition of resistance to cancer treatments. MiR-542-3p serves as a potent tumor suppressor molecule by targeting tumor suppressor p53 and apoptosis inhibitor survivin. A hyaluronic acid (HA)-decorated polyethylenimine-poly( d , l -lactide-co-glycolide) (PEI-PLGA) nanoparticle system was developed in this study for targeted co-delivery of doxorubicin (DOX) and miR-542-3p for triple negative breast cancer (TNBC) therapy. This system showed an average size at 131.7 nm and high drug encapsulation efficiency, and prevented miR-542-3p degradation in the serum. HA/PEI-PLGA nanoparticles increased both drug uptake and cytotoxicity in MDA-MB-231 cells compared to MCF-7 cells, which express lower CD44 levels. Intracellular restoration of miR-542-3p further promoted TNBC cell apoptosis via activating p53 and inhibiting survivin expression. These results indicate that HA/PEI-PLGA nanoparticles have the potential to co-deliver chemotherapeutic agents and tumor suppressive miRNAs in combinatorial TNBC therapy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26711968</pmid><doi>10.1016/j.nano.2015.09.014</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1549-9634 |
| ispartof | Nanomedicine, 2016-02, Vol.12 (2), p.411-420 |
| issn | 1549-9634 1549-9642 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1790956381 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - pharmacology Apoptosis Apoptosis - drug effects Breast - drug effects Breast - metabolism Breast - pathology Breast cancer Cell Line, Tumor Doxorubicin Doxorubicin - administration & dosage Doxorubicin - pharmacology Drug Carriers - chemistry Female Gene Expression Regulation, Neoplastic Genetic Therapy Humans Hyaluronic acid Hyaluronic Acid - chemistry Internal Medicine Lactic Acid - chemistry MicroRNA MicroRNAs - administration & dosage MicroRNAs - pharmacology Nanoparticles - chemistry Polyethyleneimine - chemistry Polyglycolic Acid - chemistry Polylactic Acid-Polyglycolic Acid Copolymer Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - pathology Triple Negative Breast Neoplasms - therapy |
| title | Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T01%3A38%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyaluronic%20acid-coated%20PEI-PLGA%20nanoparticles%20mediated%20co-delivery%20of%20doxorubicin%20and%20miR-542-3p%20for%20triple%20negative%20breast%20cancer%20therapy&rft.jtitle=Nanomedicine&rft.au=Wang,%20Shengpeng,%20MS&rft.date=2016-02-01&rft.volume=12&rft.issue=2&rft.spage=411&rft.epage=420&rft.pages=411-420&rft.issn=1549-9634&rft.eissn=1549-9642&rft_id=info:doi/10.1016/j.nano.2015.09.014&rft_dat=%3Cproquest_cross%3E1790956381%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1790956381&rft_id=info:pmid/26711968&rft_els_id=1_s2_0_S1549963415005948&rfr_iscdi=true |